Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Absci Corporation - Common Stock (NQ:ABSI)

3.390 -0.250 (-6.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Absci Corporation - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization
From Absci Corporation
Via GlobeNewswire
News headline image
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs 
From Absci Corporation; Oracle; AMD
Via GlobeNewswire
News headline image
Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg
World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia. 
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces Pricing of Public Offering of Common Stock
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces Proposed Public Offering of Common Stock
From Absci Corporation
Via GlobeNewswire
News headline image
iRhythm Technologies Announces Board Member Retirements and New Director Appointments
From iRhythm
Via GlobeNewswire
News headline image
Absci Appoints Biopharma Leader Mary Szela to Board of Directors
Former Abbott executive who led the US launch and global expansion of Humira® adds three decades of commercial and clinical leadership expertise 
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in the KeyBanc Capital Markets Healthcare Forum
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in the TD Cowen 45th Annual Health Care Conference
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
From Absci Corporation
Via GlobeNewswire
News headline image
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class... 
From Absci Corporation; Owkin
Via GlobeNewswire
News headline image
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software 
From Absci Corporation
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.